Target spd0410 for diseases caused by streptococcus pneumoniae infection and application of target spd0410
By deleting the spd0410 gene as a whole or partially or inhibiting the capsular expression of Streptococcus pneumoniae, the problem of limited coverage of existing vaccines and drug-resistant bacteria is solved, new antibacterial targets are provided, and the ability to control Streptococcus pneumoniae infection is improved .
Patent Information
- Application Number
- CN202411122225.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-15
- Publication Date
- 2024-11-19
AI Technical Summary
The existing vaccine against Streptococcus pneumoniae has limited serotypes, which is difficult to effectively control infection, and the increase in drug-resistant bacteria, resulting in difficulty in treatment.
By deleting or inhibiting the spd0410 gene as a whole or partially, interfering with its expression, thereby changing the expression level of the capsular polysaccharide and the thickness of the surface capsule, reducing the virulence of Streptococcus pneumoniae.
New targets are provided to prevent and treat Streptococcus pneumoniae infection, enhance control over the bacteria, and improve disease prevention and treatment effects.
Smart Images

Figure CN118979004A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and specifically relates to a disease target spd0410 caused by Streptococcus pneumoniae infection and an application thereof. Background Art
[0002] Streptococcus pneumoniae (S.pn) is a common Gram-positive pathogenic bacterium. Its main pathogenic substances are pneumolysin, capsule, and purpura-forming factor. The capsule is antigenic and is the basis for the classification of Streptococcus pneumoniae. Streptococcus pneumoniae can cause lobar pneumonia, meningitis, bronchitis, otitis media, endocarditis, bacteremia, and other diseases. Streptococcus pneumoniae is the main pathogenic bacterium of community-acquired pneumonia, with an average global incidence of up to 27.3%, which brings a huge burden to clinicians and patients. Due to the increase in drug-resistant bacteria and the poor effect of existing vaccines, it is urgent to deeply understand the invasive pathogenic mechanism of Streptococcus pneumoniae in order to provide a new basis for effectively controlling Streptococcus pneumoniae infection. Vaccines are an important means of controlling bacterial infections, but the existing vaccines for Streptococcus pneumoniae on the market currently have the following problems: limited serotypes covered, capsule serotype conversion, etc., which makes it difficult for vaccines to effectively control infections.
[0003] Normally, when Streptococcus pneumoniae colonizes the nasopharynx of healthy people, it does not cause disease. Only under specific selection pressures will the expression of some virulence genes of Streptococcus pneumoniae be upregulated or downregulated, thereby enhancing its pathogenicity and leading to severe infections such as invasive pneumonia and even sepsis. The transition from colonization of the nasopharynx to inducing invasive diseases marks a key point in the relationship between Streptococcus pneumoniae and the host. In this process, the expression or exposure of some important virulence factors of bacteria (such as capsule, teichoic acid, CbpA, Hyl, Ply, PspA, LytA, etc.) has undergone significant changes. Among them, the capsule (CPS) is a very critical virulence factor, which is necessary for effective colonization of the host's nasopharynx and invasive infections in the blood and lungs. In order to colonize the nasopharynx, Streptococcus pneumoniae will reduce the synthesis of the capsule to increase the exposure of surface structures such as adhesins required for initial colonization. When Streptococcus pneumoniae escapes from the nasopharynx and invades the lungs and blood, the high expression of the capsule can mask bacterial surface antigens and reduce complement deposition, thereby protecting the bacteria from opsonophagocytosis. The capsule plays an important role in the process of Streptococcus pneumoniae escaping the killing of the host's natural immune system and invasively causing pathogenicity to the host. Clinical strains of Streptococcus pneumoniae isolated from sterile parts of the human body all contain thick capsules, while strains without capsules almost lose their virulence. All these make the diseases caused by Streptococcus pneumoniae face huge problems in the treatment, so there is an urgent need to find new drug targets to develop new antibacterial drugs.
[0004] In summary, the current treatment of pneumococcal infection faces the problem of difficult-to-control drug-resistant bacteria, so the discovery and identification of new antibiotic targets is urgently needed. Summary of the invention
[0005] In view of this, the purpose of the present invention is to provide an application of spd0410, a disease target caused by Streptococcus pneumoniae infection, to effectively prevent and treat diseases caused by Streptococcus pneumoniae infection.
[0006] In a first aspect, the present invention provides an engineered Streptococcus pneumoniae, wherein the genome of the engineered Streptococcus pneumoniae is completely or partially missing the spd0410 gene;
[0007] Or, the activity of the spd0410 gene in the engineered Streptococcus pneumoniae is inhibited;
[0008] and / or, the expression level of the protein encoded by the spd0410 gene in the engineered Streptococcus pneumoniae is reduced;
[0009] The spd0410 gene includes itself and its homologous genes or alleles.
[0010] In a second aspect, the present invention also provides a method for preparing the engineered Streptococcus pneumoniae as described above, the method comprising:
[0011] The spd0410 gene in Streptococcus pneumoniae is completely or partially deleted by gene knockout, gene knockdown, sequence point mutation or sequence point deletion;
[0012] and / or, using a monoclonal antibody against spd0410, a polyclonal antibody against spd0410, a small molecule compound, a natural extract, CRISPR / Cas technology, SiRNA technology or a technology for changing the spd0410 promoter region to inhibit the activity of the spd0410 gene in Streptococcus pneumoniae and / or reduce the expression level of the protein encoded by the spd0410 gene in Streptococcus pneumoniae;
[0013] The spd0410 gene includes itself and its homologous genes or alleles.
[0014] In a third aspect, the present invention also provides use of engineered Streptococcus pneumoniae in the preparation of a vaccine for preventing diseases caused by Streptococcus pneumoniae infection, wherein the genome of the engineered Streptococcus pneumoniae is entirely or partially deficient in the spd0410 gene.
[0015] Optionally, the disease comprises at least one of bacteremia, sepsis, pneumonia, meningitis, otitis media and endocarditis.
[0016] In a fourth aspect, the present invention also provides an application of a biological model in screening drugs for preventing or treating diseases caused by Streptococcus pneumoniae infection, wherein the biological model comprises an engineered Streptococcus pneumoniae bacterium, wherein the genome of the engineered Streptococcus pneumoniae bacterium entirely or partially lacks the spd0410 gene, or the activity of the spd0410 gene is inhibited and / or the expression level of the protein encoded by the spd0410 gene is reduced, and the spd0410 gene comprises itself and its homologous genes or alleles.
[0017] In a fifth aspect, the present invention also provides the use of the spd0410 gene and / or the protein encoded by the spd0410 gene as a target in the preparation of the diagnosis, prognosis evaluation or efficacy evaluation of diseases caused by Streptococcus pneumoniae infection, characterized in that the spd0410 gene or the protein is used as a biomarker for preparing or screening diagnostic reagents for diseases caused by Streptococcus pneumoniae infection, and the reagents are used for the diagnosis and / or prognosis and / or treatment monitoring of diseases caused by Streptococcus pneumoniae infection, and the spd0410 gene includes itself and its homologous genes or alleles.
[0018] Optionally, the reagent is used to determine the activity of the spd0410 gene and / or the expression level of the protein encoded by the spd0410 gene.
[0019] Optionally, the activity of the spd0410 gene and / or the expression level of the protein encoded by the spd0410 gene is negatively correlated with the severity of the disease caused by Streptococcus pneumoniae infection.
[0020] Optionally, the reagent is used to diagnose or monitor the presence and / or course and / or severity and / or prognosis of a disease caused by S. pneumoniae infection.
[0021] In a sixth aspect, the present invention also provides the use of the spd0410 gene and / or the protein encoded by the spd0410 gene as a target in the preparation of a drug for preventing or treating diseases caused by Streptococcus pneumoniae infection, wherein the spd0410 gene includes itself and its homologous genes or alleles.
[0022] As described above, the disease target spd0410 caused by Streptococcus pneumoniae infection and its application of the present invention have the following beneficial effects:
[0023] Through research, the present application has found that by targeting the spd0410 gene (including itself and its homologous genes or alleles) and / or the protein encoded by the spd0410 gene, the activity of the corresponding gene and / or the expression level of its encoded protein can be adjusted, thereby changing the function and activity of the spd0410 gene and its encoded protein, so that the expression level of the capsular polysaccharide of Streptococcus pneumoniae changes, the surface capsule thickness changes, and ultimately the virulence of Streptococcus pneumoniae changes, thereby providing new targets for the prevention, treatment, prognosis assessment and treatment monitoring of diseases caused by Streptococcus pneumoniae infection. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 is the nucleotide sequence of the SPD_0410 (i.e., spd0410) gene;
[0025] Figure 2 PCR (polymerase chain reaction) results for constructing up, erm, down, up-erm-down fragments of D39ΔSPD_0410-deficient Streptococcus pneumoniae and spd0410 gene fragments of D39ΔSPD_0410-ectopic complementing strains;
[0026] Figure 3 These are the growth curves of wild-type Streptococcus pneumoniae D39, D39ΔSPD_0410-deficient strains, and D39ΔSPD_0410-ectopically complemented strains;
[0027] Figure 4 The transmission electron microscopic morphology of Streptococcus pneumoniae D39 wild strain, D39ΔSPD_0410 defective strain and D39ΔSPD_0410 ectopically complemented strain;
[0028] Figure 5 The results of the CPS expression level (Western-bolt test) of Streptococcus pneumoniae D39 wild-type bacteria, D39ΔSPD_0410 defective bacteria and D39ΔSPD_0410 ectopically complemented bacteria are shown in the figure;
[0029] Figure 6 The results of the CPS expression level (ELISA test) of Streptococcus pneumoniae D39 wild strain, D39ΔSPD_0410 defective strain and D39ΔSPD_0410 ectopically complemented strain are shown in the figure;
[0030] Figure 7 The graphs are the test results of CPS content (detected by uronic acid method) of wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410 and ectopic complementing D39ΔSPD_0410. A is the test result of whole bacteria sample, and B is the test result of cell wall sample.
[0031] Figure 8This is the result of the detection of cps gene mRNA transcription level (qRT-PCR detection) of wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410;
[0032] Fig. 9 The SPD_0410 protein binds to the promoter region of Streptococcus pneumoniae D39cps (DNase Ifootprinting assay analysis);
[0033] Fig.10 The following are the results of the A549 cell adhesion and invasion assay of wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410. A is the adhesion number assay result, and B is the invasion rate assay result.
[0034] Fig.11 The figures are the results of the anti-macrophage phagocytosis test of wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410, wherein A is the adhesion number test result figure, and B is the anti-phagocytosis rate test result figure;
[0035] Fig.12 This is a graph showing the experimental test results of the survival rate of mice after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410;
[0036] Fig.13 Figure 2 is a graph showing the results of an experimental test on the bacterial load of mice 48 hours after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 bacteria. Figure 3 is a graph showing the results of an experimental test on the bacterial load of mice 48 hours after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 bacteria in nasopharyngeal lavage fluid. Figure 48 is a graph showing the results of an experimental test on the bacterial load of mice 48 hours after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 bacteria in lung tissue homogenate. Figure 48 is a graph showing the results of an experimental test on the bacterial load of mice 48 hours after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 bacteria in spleen tissue homogenate. Figure 48 is a graph showing the results of an experimental test on the bacterial load of mice 48 hours after nasal infection with wild Streptococcus pneumoniae D39ΔSPD_0410 bacteria in cardiac blood. DETAILED DESCRIPTION
[0037] The present invention is further described below through specific examples, but it should be pointed out that the specific material ratios, process conditions and results described in the embodiments of the present invention are only used to illustrate the present invention and cannot be used to limit the scope of protection of the present invention. All equivalent changes or modifications made according to the spirit of the present invention should be included in the scope of protection of the present invention.
[0038] The present application has found through a series of studies that the SPD_0410 gene (its nucleotide sequence is as follows) is completely or partially deleted in Streptococcus pneumoniae. Figure 1 The present invention discloses a novel novel gene encoding SPD_0410, a pneumococcal infection-associated streptococcus pneumoniae, and a pneumococcal infection-associated streptococcus pneumoniae. The gene encoding SPD_0410 and its homologous genes or alleles thereof can interfere with or inhibit the expression of the SPD_0410 gene and its encoded product, thereby inhibiting the activity of the SPD_0410 gene, causing an increase in the expression of bacterial capsular polysaccharides, thickening of the surface capsule, and ultimately enhancing the virulence of the bacteria, thereby providing new targets for the prevention, treatment, prognosis assessment, and treatment monitoring of diseases caused by pneumococcal infection.
[0039] The present invention is described in detail below by specific examples. It should also be understood that the following examples are only used to specifically illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the above content of the present invention belong to the scope of protection of the present invention. The specific process parameters and the like in the following examples are also only examples within a suitable range, that is, those skilled in the art can make a selection within a suitable range through the description herein, and are not limited to the specific values exemplified below.
[0040] (I) Preparation of engineered Streptococcus pneumoniae
[0041] Preparation of engineered Streptococcus pneumoniae bacteria, the specific steps are as follows:
[0042] 1.1 Raw materials: Streptococcus pneumoniae D39, wild strain of Streptococcus pneumoniae D39, bacterial DNA extraction kit was purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd., Prime Star high-fidelity enzyme, dNTPs, Buffer and MgCl2 for PCR (polymerase chain reaction) were purchased from Bao Biotechnology (Dalian) Co., Ltd., PCR (polymerase chain reaction) product purification kit and gel recovery kit were purchased from Roche Diagnostics (Shanghai) Co., Ltd., the competent stimulatory peptide (CSP1) was synthesized by Shanghai Qiangyao Biotechnology Co., Ltd., and the PCR (polymerase chain reaction) instrument was T100 from Bio-Rad, USA.
[0043] 1.2 Design and synthesis of primers:
[0044] Using the genomic DNA of Streptococcus pneumoniae D39 as a template and referring to its full sequence, primers were designed using primer premier5 software. The designed primers (specifically primers for up fragment amplification, primers for down fragment amplification, primers for erm (erythromycin gene) fragment amplification and primers for spd0410 gene fragment amplification) are shown in Table 1. All primers were commissioned to Bioengineering (Shanghai) Co., Ltd. for synthesis.
[0045] 1.3 The primers in step 1.2 include four types, namely primers for up fragment amplification, primers for down fragment amplification, primers for erm (erythromycin gene) fragment amplification and primers for spd0410 gene fragment amplification, as shown in Table 1:
[0046] Table 1 Nucleotide sequence table
[0047]
[0048]
[0049] The up fragment amplification system is: ddH2O 31.5μL, 5× buffer (Mg 2+ ) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P1 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P2 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, DNA template (i.e. Streptococcus pneumoniae D39 genomic DNA) 2 μL, prime star high-fidelity enzyme 0.5 μL;
[0050] The reaction conditions for up fragment amplification are: first amplify at 98°C for 10s, then amplify at 56°C for 15s, then amplify at 72°C for 90s, cycle amplification 30 times, and then amplify at 72°C for 10min to complete the amplification of the up fragment and obtain the up fragment;
[0051] Down fragment amplification system: ddH2O 31.5μL, 5× buffer (Mg 2+ ) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P3 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P4 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, DNA template (i.e. Streptococcus pneumoniae D39 genomic DNA) 2 μL, Prime Star high-fidelity enzyme 0.5 μL;
[0052] The down fragment amplification reaction conditions are as follows: first amplify at 98°C for 10 seconds, then amplify at 56°C for 15 seconds, then amplify at 72°C for 50 seconds, cycle amplification 32 times, and then amplify at 72°C for 5 minutes to complete the down fragment amplification and obtain the down fragment;
[0053] The erm fragment amplification system is: ddH2O 31.5μL, 5× buffer (Mg 2+) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P5 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P6 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, DNA template (i.e. Streptococcus pneumoniae D39 genomic DNA) 2 μL, prime star high-fidelity enzyme 0.5 μL;
[0054] The reaction conditions for amplifying the erm fragment are as follows: amplify at 98°C for 10 seconds, then at 55°C for 15 seconds, then at 72°C for 60 seconds, cycle amplification 30 times, and then amplify at 72°C for 10 minutes to complete the amplification of the erm fragment and obtain the erm fragment;
[0055] The spd0410 gene fragment amplification system is: ddH2O 31.5μL, 5× buffer (Mg 2+ ) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P7 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P8 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, DNA template (i.e. Streptococcus pneumoniae D39 genomic DNA) 2 μL, prime star high-fidelity enzyme 0.5 μL;
[0056] The reaction conditions for amplifying the spd0410 gene fragment are as follows: amplify at 98°C for 10 seconds, then at 56°C for 15 seconds, then at 72°C for 60 seconds, cycle amplification 30 times, then amplify at 72°C for 10 minutes to complete the amplification of the spd0410 gene fragment and obtain the spd0410 gene fragment;
[0057] 1.4 Purify the up fragment, down fragment and erm fragment amplified in step 1.3 using a PCR (polymerase chain reaction) product purification kit;
[0058] 1.5 Perform PCR (polymerase chain reaction) amplification of the SPD_0410up-erm-SPD_0410down junction fragment on the up fragment, down fragment and erm fragment purified in step 1.4;
[0059] The molar ratio of each substance is: primer (i.e. P1 or P4): DNA template = 1:40, up fragment: erm fragment: down fragment = 1:1:1; the volume of each substance amplified is: ddH2O 30.5μL, 5× buffer (Mg 2+) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P1 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P4 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, up fragment 1 μL, down fragment 1 μL, erm fragment 1 μL, prime star high-fidelity enzyme 0.5 μL;
[0060] The amplification reaction conditions were as follows: amplification at 98°C for 10 seconds, followed by amplification at 56°C for 15 seconds, and then at 72°C for 3 minutes. After 33 cycles of amplification, amplification was completed at 72°C for 10 minutes to obtain the coding product SPD_0410up-erm-SPD_0410down.
[0061] 1.6 Use a gel recovery kit to recover the coding product SPD_0410up-erm-SPD_0410down obtained in step 1.5 to obtain a SPD_0410up-erm-SPD_0410down connection PCR (polymerase chain reaction) fragment gel recovery product;
[0062] 1.7 The wild-type Streptococcus pneumoniae D39 strain was cultured in C+Y medium containing 1×BSA+CaCl2 (the concentration of BSA was 0.1 g / L and the concentration of CaCl2 was 0.018 wt%) at 37°C and 5% carbon dioxide;
[0063] When the strain density reaches A 600 (i.e., absorbance at 600 nm) was 0.1, 10 μL of competent stimulator (CSP1) was added to 90 μL of C+Y medium, and incubated in a 37°C water bath for 10 min, followed by adding 10 μL of SPD_0410up-erm-SPD_0410down ligation PCR (polymerase chain reaction) fragment gel to recover the product, and placing on ice for 30 min;
[0064] Incubate in a 37°C water bath for 90 minutes, then spread on a TSA blood plate containing 0.25 mg / L erythromycin, and culture in a 37°C incubator for 24-48 hours. The pneumococci that have successfully integrated the erm fragment will grow on the TSA blood plate containing erythromycin to form colonies.
[0065] 1.8 Pick a single colony from 1.7 and culture it in C+Y medium at 37°C and 5% carbon dioxide;
[0066] When the bacterial density of the colony reaches A 600=0.5, mixed with 50% glycerol (concentration here is w / v, specifically 50 g / L) at a volume ratio of 7:3 and stored in a -80°C refrigerator to obtain the D39-deficient strain of Streptococcus pneumoniae in which the SPD_0410 gene was replaced by the erm gene (hereinafter referred to as D39ΔSPD_0410-deficient strain);
[0067] 1.9 The pneumococcal D39 defective bacteria obtained in step 1.8 are cultured in C+Y medium at 37°C and 5% carbon dioxide;
[0068] Density of defective bacteria A 600 When the absorbance at 600 nm was 0.5, the DNA was extracted using a DNA extraction kit, and the SPD_0410up-erm-SPD_0410down three-segment connected gene fragment was amplified in a PCR (polymerase chain reaction) instrument using SPD_0410-P1 (i.e. P1) and SPD_0410-P4 (i.e. P4) as primers;
[0069] The amplification system is: ddH2O 31.5μL, 5× buffer (Mg 2+ ) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P1 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P4 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, DNA template (i.e. Streptococcus pneumoniae D39ΔSPD_0410 genomic DNA) 2 μL, Prime Star high-fidelity enzyme 0.5 μl;
[0070] The amplification reaction conditions were as follows: amplification at 98°C for 10 s, followed by amplification at 56°C for 15 s, and then at 72°C for 50 s, 32 cycles of amplification, and then at 72°C for 5 min to complete the amplification of the SPD_0410up-erm-SPD_0410down fragment;
[0071] Use gel recovery kit to recover and purify, the results are as follows Figure 2 As shown, the Chinese company Qingke was commissioned to carry out gene sequencing;
[0072] Depend on Figure 2 It can be seen that the size of the gene fragment of the three fragments SPD_0410up-erm-SPD_0410down is correct. This result shows that the three fragments SPD_0410up-erm-SPD_0410down were successfully transferred into the Streptococcus pneumoniae D39 strain, and the sequencing results showed no base mutation, that is, the Streptococcus pneumoniae D39ΔSPD_0410 strain was successfully constructed;
[0073] 1.10 Purify the spd0410 gene fragment amplified in step 1.3 using a PCR (polymerase chain reaction) product purification kit;
[0074] 1.11 The purified spd0410 gene fragment obtained in step 1.10 and plasmid pPEPZ were double-digested with restriction endonucleases BgIII and XhoI at 37°C for 1 h;
[0075] The enzyme digestion system is as follows: 10× QuickCut Buffer 2 μL, DNA template (i.e., spd0410 gene fragment and plasmid pPEPZ DNA) 0.2-1.0 μg, BgIII (concentration 10 U / μL, commercially available) 1 μL, XhoI (concentration 10 U / μL, commercially available) 1 μL, ddH2O to 20 μL;
[0076] The enzyme digestion conditions are: constant temperature reaction at 37°C for 1 h to obtain the enzyme digestion product;
[0077] Use gel recovery kit for recovery and purification;
[0078] 1.12 Ligate the spd0410 gene fragment obtained in step 1.11 with the restriction digestion product of plasmid pPEPZ using T4 ligase;
[0079] The ligation system is as follows: 10×T4 DNA ligase buffer 2 μL, spd0410 gene fragment digestion product 37.5 ng, plasmid pPEPZ digestion product 50 ng, T4 DNA ligase (concentration 400 U / μL, commercially available) 1 μL, ddH2O to 20 μL;
[0080] The ligation system is as follows: the reaction is carried out at 16°C overnight to obtain the pPEPZ-spd0410 ligation product;
[0081] 1.13 The pPEPZ-spd0410 ligation product obtained in step 1.12 was transformed into competent cells DH5a, placed on ice for 30 minutes, then in a 42°C water bath for 90 seconds, 900 μl LB was added, and cultured at 37°C on a shaker at 180 rpm for 2 hours. The supernatant was removed by centrifugation, and the remaining 90 μl was evenly spread on an LB plate containing 50 μg / ml spectinomycin resistance, and cultured in a 37°C incubator for 24-48 hours;
[0082] 1.14 Pick a single colony from 1.13, use primers P7 and P8 to amplify the spd0410 fragment in a PCR (polymerase chain reaction) instrument, screen the positive monoclonal colonies, expand the positive monoclonal colonies, extract the plasmid and entrust China Qingke Company to perform gene sequencing to obtain the pPEPZ-spd0410 plasmid.
[0083] 1.15 The pneumococcal D39ΔSPD_0410 defective bacteria were cultured in C+Y medium containing 1×BSA+CaCl2 (the concentration of BSA was 0.1 g / L and the concentration of CaCl2 was 0.018 wt%) at 37°C and 5% carbon dioxide;
[0084] When the strain density reaches A 600 (i.e., absorbance at 600 nm) was 0.1, 10 μL of competent stimulator (CSP1) was added to 90 μL of C+Y medium, and incubated in a water bath at 37°C for 10 min, followed by the addition of pPEPZ-spd0410 plasmid DNA, and placed on ice for 30 min;
[0085] Then incubate in a 37°C water bath for 90 minutes, then plate on a TSA blood plate containing 50 μg / ml spectinomycin, and culture at 37°C and 5% carbon dioxide for 24-48 hours. S. pneumoniae that has successfully integrated the pPEPZ-spd0410 plasmid DNA will grow on the TSA blood plate containing spectinomycin to form colonies;
[0086] 1.16 Pick a single colony from 1.15 and culture it in C+Y medium at 37°C and 5% carbon dioxide;
[0087] When the bacterial density of the colony reaches A 600 =0.5, mixed with 50% glycerol (concentration here is w / v, specifically 50 g / L) at a volume ratio of 7:3 and stored in a -80°C refrigerator to obtain the SPD_0410 gene complementing Streptococcus pneumoniae D39ΔSPD_0410Com ectopic complementing strain (hereinafter referred to as D39ΔSPD_0410 ectopic complementing strain);
[0088] 1.17 The pneumococcal D39ΔSPD_0410 ectopic complement obtained in step 1.16 was placed in C+Y medium and cultured at 37°C and 5% carbon dioxide;
[0089] Density of bacteria to be replenished A 600 When the absorbance at 600 nm was 0.5, DNA was extracted using a DNA extraction kit, and the spd0410 gene fragment was amplified in a PCR (polymerase chain reaction) instrument using P7 and P8 as primers;
[0090] The amplification system is: ddH2O 31.5μL, 5× buffer (Mg 2+) 10 μL, dNTP (i.e. deoxynucleoside triphosphate, concentration is 2.5 mM, commercially available) 4 μL, P7 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, P8 (concentration is 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.) 1 μL, DNA template (i.e. genomic DNA of ectopically complemented Streptococcus pneumoniae D39ΔSPD_0410) 2 μL, Prime Star high-fidelity enzyme 0.5 μl;
[0091] The amplification reaction conditions were as follows: amplification at 98°C for 10 s, followed by amplification at 56°C for 15 s, and then at 72°C for 50 s, 32 cycles of amplification, and then at 72°C for 5 min to complete the amplification of the spd0410 gene fragment;
[0092] Use gel recovery kit to recover and purify, the results are as follows Figure 2 As shown, the Chinese company Qingke was commissioned to carry out gene sequencing;
[0093] Depend on Figure 2 It can be seen that the size of the spd_0410 gene fragment is correct. This result shows that the pPEPZ-spd0410 plasmid DNA was successfully transferred into the S. pneumoniae D39ΔSPD_0410 defective strain, and the sequencing results showed no base mutation, that is, the S. pneumoniae D39ΔSPD_0410 ectopic complementation strain was successfully constructed.
[0094] (II) Growth curve determination
[0095] The growth curves of wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410 and ectopic complementing D39ΔSPD_0410 were determined as follows:
[0096] 2.1 Wild-type Streptococcus pneumoniae D39 (D39 WT for short), D39ΔSPD_0410 defective strain (D39ΔSPD_0410 for short), and D39ΔSPD_0410 ectopic complementing strain (D39ΔSPD_0410Com for short) were inoculated into blood agar plates and cultured overnight at 37°C and 5% carbon dioxide until the absorbance at 600 nm was A 600 was 0.5, and the blood plate was washed with PBS;
[0097] 2.2 Dilute the bacterial solution 10 times, take 100 μL of the bacterial solution and add it to 5 mL of C+Y medium. There are three groups: D39WT, D39ΔSPD_0410 and D39ΔSPD_0410Com. The absorbance value A is measured every 1 hour. 600 (i.e. absorbance at 600nm wavelength) and record the absorbance value;
[0098] 2.3 Draw a growth curve with absorbance as the ordinate and time point as the abscissa. The results are as follows: Figure 3 As shown in the figure, OD 600 That is, the absorbance at a wavelength of 600nm is A 600 .
[0099] Depend on Figure 3 It can be seen that the growth levels of each group are basically the same. This result shows that the loss of spd0410 gene has almost no effect on the growth of Streptococcus pneumoniae.
[0100] (III) Transmission electron microscopy scanning
[0101] Transmission electron microscopy scanning was performed on the cultured Streptococcus pneumoniae D39 wild strain, D39ΔSPD_0410 defective strain and D39ΔSPD_0410 ectopic complementing strain. The specific steps are as follows:
[0102] 3.1 Wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410 and ectopic complemented D39ΔSPD_0410 were inoculated into blood plates and cultured overnight at 37°C and 5% carbon dioxide;
[0103] 3.2 Transfer the overnight grown strain into fresh C+Y medium and culture at 37°C and 5% carbon dioxide until A 600 (i.e. absorbance at 600nm wavelength) is 0.5;
[0104] 3.3 Collect 1 mL of bacteria, centrifuge at 10,000 rpm for 15 min, and rinse twice with PBS buffer;
[0105] 3.4 After discarding the supernatant, slowly add 1 mL of 2.5% glutaraldehyde fixative along the tube wall. Do not suspend the bacteria and fix them at 4°C overnight.
[0106] 3.5 Wuhan Saiweier Biotechnology Co., Ltd. was commissioned to conduct subsequent electron microscopy processing and analysis. The results are as follows Figure 4 shown.
[0107] Depend on Figure 4 It can be seen that compared with wild-type Streptococcus pneumoniae D39, the surface capsule of Streptococcus pneumoniae D39ΔSPD_0410-deficient bacteria was thickened, while the ectopic complement of Streptococcus pneumoniaeΔSPD_0410 restored it to the level of wild-type bacteria. This result shows that the loss of the spd0410 gene leads to an increase in the synthesis of capsular polysaccharides in Streptococcus pneumoniae.
[0108] (IV) CPS expression detection (Western blot method)
[0109] The CPS expression level of Streptococcus pneumoniae D39 wild-type bacteria, D39ΔSPD_0410 defective bacteria and D39ΔSPD_0410 ectopic complementing bacteria was detected (Western blot method), and the specific steps are as follows:
[0110] 4.1 Sample collection: Wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410, and ectopic complemented D39ΔSPD_0410 were inoculated onto blood plates and cultured at 37°C and 5% carbon dioxide until A 600 (i.e., absorbance at 600 nm) was 0.5, 5 mL of bacterial solution was collected, centrifuged at 4°C and 12,000 r / min for 5 min, washed twice with PBS buffer, and the supernatant was discarded;
[0111] The bacterial precipitate was treated with 200 μL SEDS lysis buffer (containing 0.1% DOC, 150 mM NaCl, 0.2% SDS and 15 mM EDTA, pH = 8), and the resuspension was lysed at 37°C for 15 min to completely dissolve the bacterial suspension until it was clear. 5× Loading Buffer was added to the sample to obtain a whole bacterial lysis protein sample;
[0112] 4.2 Prepare 12.5% SDS-PAGE gel and perform tris-glycine SDS electrophoresis: upper layer concentration gel electrophoresis 80V, 40min; lower layer separation gel electrophoresis: 120V, 1h; transfer to membrane 210mA, 3h, transfer the band to PVDF membrane;
[0113] 4.3 Block the membrane with 5% skimmed milk powder at 37°C for 2 h, then wash the membrane three times with TBST, each time for 15 min;
[0114] 4.4 Add primary antibodies to the system (specifically rabbit anti-CPS IgG and Mouse anti-GAPDH IgG, the volume ratio of rabbit anti-CPS IgG to the system is 1:500, and the volume ratio of Mouse anti-GAPDH IgG to the system is 1:5000) and mix, and incubate the primary antibodies on a shaker at 4°C overnight;
[0115] 4.5 The product obtained by incubation in 4.4 was washed with TBST three times, each time for 15 minutes, and then the secondary antibody was added (specifically rabbit anti-goat anti-rabbit IgG, mouse anti-goat anti-mouse IgG, the volume ratio of rabbit anti-goat anti-rabbit IgG and mouse anti-goat anti-mouse IgG to the system was 1:10000), and incubated at 37°C for 1 hour;
[0116] 4.6 After the incubation in step 4.5 is completed, wash the membrane three times with TBST, each time for 15 minutes, add the freshly prepared ECL reaction solution (Millipore) and react for 1 minute. Use the Bio-Rad ChemiDocXRS+ imager to image. The results are as follows: Figure 5 shown.
[0117] Depend on Figure 5 It can be seen that compared with wild-type Streptococcus pneumoniae D39, the expression of capsular polysaccharide in the defective Streptococcus pneumoniae D39ΔSPD_0410 strain increased significantly, while the ectopic complement of Streptococcus pneumoniaeΔSPD_0410 strain restored the level to that of wild-type strains. This result indicates that the loss of the spd0410 gene leads to an increase in the synthesis of capsular polysaccharides in Streptococcus pneumoniae.
[0118] (V) CPS expression detection (ELISA method)
[0119] The CPS expression level of Streptococcus pneumoniae D39 wild strain, D39ΔSPD_0410 defective strain and D39ΔSPD_0410 ectopic complement strain was detected (ELISA method), and the specific steps are as follows:
[0120] 5.1 Materials: Rabbit anti-anti-CPS antiserum was purchased from Statens Serum Institut, Denmark, horseradish peroxidase-labeled goat anti-mouse IgG antibody (i.e., Goat anti-rabbit IgG) was purchased from Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., and horseradish peroxidase-labeled goat anti-mouse IgA secondary antibody was purchased from Santa Cruz Biotechnology, Inc. (USA).
[0121] 5.2 Sample collection: Wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410, and ectopic complemented D39ΔSPD_0410 were inoculated into C+Y medium and cultured overnight at 37°C and 5% carbon dioxide until A 600 (i.e., absorbance at 600nm wavelength) was 0.5. 5mL of bacterial solution was collected from each group of bacteria, centrifuged at 12000rpm and 4℃ for 5min, and the supernatant was collected. The supernatant was filtered with a 0.24μm filter and placed on ice for later use. The bacterial precipitate was resuspended with sterile PBS buffer, and the resuspended solution was treated in a 58℃ water bath for 45min. After sterilization, the supernatant was removed by centrifugation, and each group of bacteria was adjusted to the same density;
[0122] 5.3 Dilute the sample with ELISA antigen coating solution in multiple ratios, coat the sample in a 96-well plate, 200 μL per well, and incubate at 4°C overnight;
[0123] 5.4 Wash the plate: Wash the plate 4 times with 0.05% PBST and tap the plate;
[0124] 5.5 Blocking: Add BSA to PBS buffer to prepare blocking solution, so that the final concentration of BSA is 2wt%. Add 200 μL of the blocking solution to each well, incubate at 37°C for 2 h, then wash the plate 4 times and tap the plate;
[0125] 5.6 Incubate with primary antibody: Add 100 μL anti-CPS primary antibody (2% BSA diluted 1:500) to each well, incubate at 37°C for 1 hour, wash the plate 5 times, and tap the plate;
[0126] 5.7 Incubate with secondary antibody: Add 100 μL of Goat anti-rabbit IgG secondary antibody (2% BSA diluted 1:5000) to each well, incubate at 37°C for 1 hour, and wash the plate 5 times;
[0127] 5.8 Color development: Add 50 μL DAB color development reagent A, then add 50 μL DAB color development reagent B, and incubate at 37°C for 15 min in a dark place;
[0128] 5.9 Stop: Add 100 μL of stop solution to each well;
[0129] 5.10 Detection: Determine the absorbance A at a wavelength of 450 450 , the results are as follows Figure 6 As shown in the figure, OD 450 That is the absorbance A at a wavelength of 450 450 .
[0130] Depend on Figure 6 It can be seen that compared with wild-type Streptococcus pneumoniae D39, the capsular polysaccharide content of Streptococcus pneumoniae D39ΔSPD_0410-deficient bacteria increased, while the ectopic complement of Streptococcus pneumoniaeΔSPD_0410 restored it to the level of wild-type bacteria. This result shows that the loss of the spd0410 gene leads to an increase in the synthesis of capsular polysaccharides in Streptococcus pneumoniae.
[0131] (VI) Determination of CPS content (uronic acid method)
[0132] The CPS content (uronic acid method) of Streptococcus pneumoniae D39 wild strain, D39ΔSPD_0410 defective strain and D39ΔSPD_0410 ectopic complement strain was detected. The specific steps are as follows:
[0133] 6.1 Whole bacteria sample testing:
[0134] 6.1.1 Transfer the bacteria grown overnight on the blood agar plate to normal C+Y medium and culture at 37°C and 5% carbon dioxide;
[0135] When it grows to the middle of logarithmic growth (i.e., the absorbance at 600nm is A600 When the concentration of the sample was 0.5), 5 mL of the sample was collected and centrifuged at 8000 × g and 4 °C for 20 min. The supernatant was removed and the precipitate was retained.
[0136] 6.1.2 Wash once with 150 mM Tris-HCl (pH = 7.0) buffer and resuspend in 500 μL Tris-HCl (pH = 7.0) buffer;
[0137] 6.1.3 Mix 200 μL of bacterial suspension with 1 mL of 0.0125 M borate solution and heat at 100°C for 5 min.
[0138] 6.1.4 After the bacterial solution has cooled to room temperature, add 16 μL of 0.15 wt% m-hydroxydiphenyl solution to each tube, mix well and let stand for 30 minutes;
[0139] 6.1.5 Detection: Detect absorbance A at 525 nm wavelength 525 , the results are as follows Figure 7 As shown in the figure, OD 525 That is, the absorbance at a wavelength of 525nm is A 525 .
[0140] 6.2 Bacterial cell wall sample detection:
[0141] 6.2.1 Transfer the bacteria grown overnight on the blood agar plate to normal C+Y medium and culture at 37°C and 5% carbon dioxide;
[0142] When it grows to the middle of logarithmic growth (i.e., the absorbance at 600nm is A 600 When the concentration of the sample was 0.5), 5 mL of the sample was collected and centrifuged at 8000 × g and 4 °C for 20 min. The supernatant was removed and the precipitate was retained.
[0143] 6.2.2 Wash twice with PBS buffer, resuspend in 500 μL PBS buffer containing 2 wt% SDS (specifically, add SDS to the PBS buffer to make the final concentration of SDS 2 wt%), heat in boiling water for 30 min, and cool to room temperature;
[0144] 6.2.3 Centrifuge at 13000rpm for 5 min, wash once with 150 mM Tris-HCl (pH=7.0) buffer, and then resuspend in 500 μL Tris-HCl (pH=7.0) buffer;
[0145] 6.2.4 Add 4 μL lysozyme (2 mg / mL) and 2.5 μL proteinase K (20 mg / mL) to the system and treat at 37°C for 30 min;
[0146] 6.2.5 Mix 200 μL of bacterial suspension with 1 mL of 0.0125 M borate solution and heat at 100°C for 5 min.
[0147] 6.2.6 After the bacterial solution has cooled to room temperature, add 16 μL of 0.15 wt% m-hydroxydiphenyl solution to each tube, mix well, and let stand for 30 minutes;
[0148] 6.2.7 Detection: Detect absorbance A at 525 nm wavelength 525 , the results are as follows Figure 7 As shown in the figure, OD 525 That is, the absorbance at a wavelength of 525nm is A 525 .
[0149] Depend on Figure 7 It can be seen that compared with wild-type Streptococcus pneumoniae D39, the capsular polysaccharide content of Streptococcus pneumoniae D39ΔSPD_0410-deficient bacteria in whole bacteria samples and cell wall samples increased, while the ectopic complement of Streptococcus pneumoniae D39ΔSPD_0410 restored it to the level of wild-type bacteria. This result shows that the loss of the spd0410 gene leads to an increase in the synthesis of capsular polysaccharides in Streptococcus pneumoniae.
[0150] (VII) mRNA transcription level detection
[0151] The mRNA transcription levels of cps2A, cps2B, cps2C, and cps2D genes of Streptococcus pneumoniae D39 wild strain and Streptococcus pneumoniae D39ΔSPD_0410 were detected. The specific steps are as follows:
[0152] 7.1 Materials: RNAprep Pure cultured cell / bacterial total RNA extraction kit was purchased from Beijing Tiangen Biochemical Technology Co., Ltd., and reverse transcription PCR (polymerase chain reaction) kit and real-time fluorescence quantitative PCR (polymerase chain reaction) kit were purchased from Bao Bioengineering (Dalian) Co., Ltd.;
[0153] 7.2 Design and synthesis of primers: Using the genomic DNA of Streptococcus pneumoniae D39 as a template and referring to its full sequence, primers were designed using the primer premier5 software: and the synthesis was commissioned to Bioengineering (Shanghai) Co., Ltd. The nucleotide sequences of the primers are shown in Table 1:
[0154] 7.3 Wild-type Streptococcus pneumoniae D39 and Streptococcus pneumoniae D39ΔSPD_0410 were cultured on blood plates at 37°C and 5% carbon dioxide overnight, then the colonies were washed with fresh C+Y medium and the bacterial suspension was diluted to A. 600 (i.e. absorbance at 600nm wavelength) to 0.03, and wait until it grows to A 600When the absorbance at 600 nm was 0.5, 3 mL of the culture was collected and centrifuged at 13,000 × g and 4 °C for 1 min;
[0155] 7.4 Then, the bacteria were thoroughly resuspended in 100 μL TE buffer containing lysozyme (the concentration of lysozyme in TE buffer was 30 mg / mL), incubated at room temperature for 10 min, and then the total RNA of bacteria was extracted according to the instructions of the culture cell / bacterial total RNA extraction kit;
[0156] 7.5 Then the RNA concentration was measured by NanArop spectrophotometer and its integrity was confirmed by 1% agarose gel electrophoresis;
[0157] 7.6 Reverse transcribe the RNA in step 7.4 using the PrimeScript cDNA First Strand Synthesis Kit to produce 1000 ng cDNA;
[0158] 7.7 Using gyrB as the internal reference gene, the cDNA obtained in step 7.6 was subjected to real-time quantitative analysis using SYBR Premix ExTaq kit, specifically: Amplification system: 0.4 μL of each primer up (i.e., containing gyrB up, Cps2A up, Cps2B up, Cps2Cup and Cps2D up, all at a concentration of 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.), 0.4 μL of each primer down (i.e., gyrB down, Cps2A down, Cps2B down, cps2C down and Cps2D down, all at a concentration of 10 mM, synthesized by Bioengineering (Shanghai) Co., Ltd.), 3.2 μL of ddH2O, 1 μL of cDNA, 5 μL of SYBR;
[0159] Amplification conditions: amplification at 95°C for 30s, then at 95°C for 10s, then at 63°C for 15s, then at 72°C for 20s, and amplification for 39 cycles. After the amplification program was completed, gyrB was used as an internal reference, and the results were visualized using Bio-Rad CFX Maestro software to obtain the relative expression of each gene. The results are shown in Figure 8 shown.
[0160] Depend on Figure 8 It can be seen that compared with wild-type Streptococcus pneumoniae D39, the mRNA transcription levels of cps2A, cps2B, cps2C and cps2D genes in Streptococcus pneumoniae D39ΔSpd_0410 were significantly increased. This result shows that the deletion of the spd0410 gene significantly increases the transcription level of the capsule gene cluster of Streptococcus pneumoniae.
[0161] (VIII) Binding site determination
[0162] The specific binding site between the SPD_0410 protein in wild Streptococcus pneumoniae D39 and the D39 cps gene promoter region was determined, and the specific steps were as follows:
[0163] 8.1 Materials: Bioengineering (Shanghai) Co., Ltd. was commissioned to synthesize the FAM-labeled Pcps probe. The nucleotide sequence of the FAM-labeled Pcps probe is shown in Table 1;
[0164] 8.2 In a 40 μL system, 300 ng of the probe was reacted with 0 μg and 0.65 μg of SPD_0410 protein, respectively, at 25°C for 30 min;
[0165] 8.3 Then, the sample was digested with 0.015 units of DNase I (Promega) at 37°C for 1 min;
[0166] 8.4 Then, the digested sample was extracted with phenol / chloroform mixed solvent (the volume ratio of phenol to chloroform was 1:1) to remove protein, and then the DNA was precipitated with ethanol;
[0167] 8.5 The precipitated DNA was dissolved in 30 μL Mili-Q ultrapure water and detected by ABI sequencer. The ladder used was ABI GeneScan500Liz. The results were as follows: Fig. 9 shown.
[0168] Depend on Fig. 9 It can be seen that the footprint experiment showed that there were two DNase I protection sites between the SPD_0410 protein and the D39 cps promoter region, indicating that the SPD_0410 protein promoted the transcription of the capsule gene cluster by specifically binding to the cps operon promoter sequence.
[0169] (IX) Adhesion and invasion assay of lung epithelial A549 cells
[0170] Adhesion and invasion experiments of wild Streptococcus pneumoniae D39 and D39ΔSPD_0410 defective bacteria on lung epithelial cells A549 were conducted. The specific steps are as follows:
[0171] 9.1 Lung epithelial cell A549 cell culture According to the laboratory SOP, 2×10 5 A549 lung epithelial cells were seeded in 24-well plates and cultured overnight at 37°C and 5% carbon dioxide.
[0172] 9.2 When the wild-type D39 bacteria and the defective D39ΔSPD_0410 bacteria were grown in C+Y medium to the mid-logarithmic growth phase (i.e., the absorbance at 600 nm was A 6000.5), collect 2 mL of bacterial solution, and centrifuge at 6000 rpm and 4 °C for 5 min;
[0173] 9.3 Wash the pellet obtained by centrifugation twice with sterile PBS buffer, and then resuspend the bacteria (i.e. the pellet obtained by centrifugation) with 4 mL of DMEM;
[0174] 9.4 Wash the cells twice with sterile PBS buffer, infect the cells at an MOI of 100, add 500 μL of bacterial solution / well, three replicates per group, and incubate at 37°C for 30 min;
[0175] 9.5 Invasion assay: discard the bacterial solution, gently rinse the cells 5 times with PBS buffer, add gentamicin and penicillin (the final concentrations of gentamicin and penicillin are 100 μg / mL and 10 μg / mL, respectively), incubate at 37°C for 15 min, then discard the antibiotics and rinse the bacteria 5 times with PBS buffer;
[0176] 9.6 Adhesion experiment: Discard the bacterial solution and gently rinse the cells 5 times with PBS buffer;
[0177] 9.7 Aspirate all the PBS buffer, add 200 μL ddH2O, and place at room temperature for 10 min to lyse the cells. Dilute the lysate by 10, 100, and 1000 times and spread on a blood agar plate. Count the cells the next day. The results are as follows: Fig.10 shown.
[0178] Depend on Fig.10 It can be seen that compared with D39 wild-type bacteria, D39ΔSPD_0410 defective bacteria have less adhesion to the surface of lung epithelial cells and more invasion of cells due to the increase in capsules. This result shows that the loss of the spd0410 gene enhances the invasive ability of Streptococcus pneumoniae.
[0179] (X) Experiment on the anti-phagocytic ability of mouse peritoneal macrophages
[0180] The anti-phagocytic ability of wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 strains on mouse peritoneal macrophages was tested. The specific steps are as follows:
[0181] 10.1 Mice were intraperitoneally injected with 1 mL of sterile paraffin oil to recruit macrophages. The mice were killed 5 days later and the peritoneal cavity was lavaged with sterile PBS buffer containing EDTA to extract primary macrophages. Macrophage culture was carried out according to laboratory SOP. The day before treatment, the macrophages were plated in 24-well plates, with a density of about 2 × 10 5 cell / well;
[0182] 10.2 After the wild-type D39 bacteria and the defective D39ΔSPD_0410 bacteria were grown in C+Y medium (cultured at 37°C and 5% carbon dioxide) to the mid-logarithmic growth phase (i.e., the absorbance at 600 nm was A 600 0.5), collect 2 mL of bacterial solution, and centrifuge at 6000 rpm and 4 °C for 5 min;
[0183] 10.3 Rinse the pellet obtained by centrifugation twice with sterile PBS buffer, and then resuspend the bacteria (i.e. the pellet obtained by centrifugation) with 4 mL of DMEM;
[0184] 10.4 Rinse the cells twice with sterile PBS buffer, add 500 μL of bacterial solution / well, three replicates per group, and incubate at 37°C for 30 min;
[0185] 10.5 Phagocytosis experiment: discard the bacterial solution, gently rinse the cells 5 times with PBS buffer, add gentamicin and penicillin (the final concentrations of gentamicin and penicillin are 100 μg / mL and 10 μg / mL, respectively), incubate at 37°C for 15 min, then discard the antibiotics and rinse the bacteria 5 times with PBS buffer;
[0186] 10.6 Adhesion experiment: Discard the bacterial solution and gently rinse the cells 5 times with PBS buffer;
[0187] 10.7 Aspirate all the PBS buffer, add 200 μL ddH2O, and place at room temperature for 10 min to lyse the cells. Dilute the lysate by 10 times, 100 times, and 1000 times, and spread on blood agar plates. Count the cells the next day. The results are as follows: Fig.11 shown.
[0188] Depend on Fig.11 It can be seen that the amount of D39ΔSPD_0410 defective bacteria adhering to the surface of macrophages and being engulfed into macrophages was significantly reduced compared with the D39 wild-type bacteria control group. This result shows that the loss of the spd0410 gene enhances the anti-phagocytic ability of Streptococcus pneumoniae.
[0189] (XI) Experiment on mouse survival rate after nasal infection
[0190] The survival rate of mice after nasal challenge with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 was tested. The specific steps are as follows:
[0191] 11.1 Wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 cultured overnight on blood agar plates were inoculated into C+Y medium and cultured at 37°C and 5% carbon dioxide until the exponential growth phase (i.e., the absorbance at 600 nm was A 600 is 0.5);
[0192] 11.2 Collect bacteria and adjust the bacterial count to 1×10 8 CFU / 30μL;
[0193] 11.3 C57 mice aged 6-8 weeks were randomly divided into 3 groups according to body weight, with 12 mice in each group, one of which was a sterile PBS negative control group;
[0194] 11.4 Mice were anesthetized with 1.5% sodium pentobarbital and challenged with 30 μL (i.e., 1×10 8 CFU);
[0195] 11.5 Every 24 hours (h), the survival rate of mice was observed and the time of death of mice was recorded. The results were analyzed by Mann-Whitney U test. Fig.12 shown.
[0196] Depend on Fig.12 It can be seen that the survival time of mice infected with D39ΔSPD_0410 defective bacteria was significantly lower than that of mice infected with D39 wild bacteria. This result shows that the loss of spd0410 gene leads to enhanced virulence of Streptococcus pneumoniae.
[0197] (XII) Experiment on bacterial load of mice 48 hours after infection
[0198] The bacterial load experiment of mice was conducted 48 hours after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410. The specific steps are as follows:
[0199] 12.1 Wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 grown overnight on blood agar plates were inoculated into C+Y medium and cultured at 37°C and 5% carbon dioxide until the exponential growth phase (i.e., the absorbance at 600 nm was A 600 is 0.5);
[0200] 12.2 Collect bacteria and adjust the bacterial count to 2×10 7 CFU / 30μL;
[0201] 12.3 6-8 week old C57 mice were randomly divided into 2 groups according to body weight, with 5 mice in each group;
[0202] 12.4 Mice were anesthetized with 1.5% sodium pentobarbital and challenged with 30 μL (i.e., 2×10 7 CFU);
[0203] 12.548 hours later, cardiac blood, nasopharyngeal lavage fluid, lung tissue and spleen tissue were homogenized; they were diluted 10 times, 100 times, 1000 times and 10000 times and spread on blood plates. The number of bacteria was counted the next day. The results were as follows: Fig.13 shown.
[0204] Depend on Fig.13 It can be seen that the bacterial loads in the blood, lung tissue homogenate and spleen tissue homogenate of mice infected with D39ΔSPD_0410-deficient bacteria were significantly higher than those of mice infected with D39 wild-type bacteria. This result shows that the loss of the spd0410 gene leads to enhanced virulence of Streptococcus pneumoniae.
[0205] In summary, the present application conducted growth curve determination on wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410 and ectopic complemented D39ΔSPD_0410 bacteria, and the results showed that the growth levels of each group were basically the same, indicating that the deletion of the spd0410 gene had almost no effect on bacterial growth.
[0206] The present application also conducted transmission electron microscopy scanning and CPS expression detection on wild Streptococcus pneumoniae D39, defective D39ΔSPD_0410 and ectopic complementing bacteria of D39ΔSPD_0410. The transmission electron microscopy scanning results showed that compared with wild Streptococcus pneumoniae D39, the surface capsule of defective Streptococcus pneumoniae D39ΔSPD_0410 was thickened, while the ectopic complementing bacteria of Streptococcus pneumoniae D39ΔSPD_0410 was restored to the level of wild bacteria; the CPS expression detection results showed that compared with wild Streptococcus pneumoniae D39, the expression of capsular polysaccharides of defective Streptococcus pneumoniae D39ΔSPD_0410 increased, while the ectopic complementing bacteria of Streptococcus pneumoniae D39 was restored to the level of wild bacteria. The above results suggest that the loss of the spd0410 gene leads to an increase in the synthesis of capsular polysaccharides of Streptococcus pneumoniae.
[0207] In order to clarify the mechanism of increased capsular polysaccharide synthesis, the present application also detected the mRNA transcription levels of cps2A, cps2B, cps2C, and cps2D genes in the wild strain of Streptococcus pneumoniae D39 and Streptococcus pneumoniae D39ΔSPD_0410. The results showed that compared with the wild strain of Streptococcus pneumoniae D39, the mRNA transcription levels of cps2A, cps2B, cps2C, and cps2D genes in Streptococcus pneumoniae D39ΔSPD_0410 were significantly increased, indicating that the deletion of the spd0410 gene significantly increased the transcription level of the capsule gene cluster.
[0208] In order to further clarify the mechanism of increased transcription level of the capsule gene cluster, the present application carried out specific binding site determination on the SPD_0410 protein and the D39 cps gene promoter region in wild Streptococcus pneumoniae D39. The results showed that there were two DNase I protection sites between the SPD_0410 protein and the D39 cps promoter region, suggesting that the SPD_0410 protein promotes the transcription of the capsule gene cluster by specifically binding to the cps operon promoter sequence.
[0209] The present application also conducted adhesion and invasion experiments on lung epithelial cells A549 cells for wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410. The results showed that compared with wild-type Streptococcus pneumoniae D39, defective D39ΔSPD_0410 bacteria adhered less to the surface of lung epithelial cells and invaded cells more due to the increased number of capsules, suggesting that the loss of the spd0410 gene enhances the invasive ability of Streptococcus pneumoniae.
[0210] The present application also conducted an experiment on the anti-phagocytic ability of mouse peritoneal macrophages with wild-type Streptococcus pneumoniae D39 and defective D39ΔSPD_0410 bacteria. The results showed that the amount of D39ΔSPD_0410 defective bacteria adhering to the macrophage surface and being phagocytosed into the macrophages was significantly reduced compared with the D39 wild-type control group, indicating that the deletion of the spd0410 gene enhances the anti-phagocytic ability of Streptococcus pneumoniae.
[0211] The present application also conducted an experiment on the survival rate of mice after nasal challenge with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410. The results showed that the survival time of mice infected with defective D39ΔSPD_0410 was significantly lower than that of mice infected with wild D39 bacteria, indicating that the deletion of the spd0410 gene leads to the enhanced virulence of Streptococcus pneumoniae.
[0212] The present application also conducted a mouse bacterial load experiment 48 hours after nasal infection with wild Streptococcus pneumoniae D39 and defective D39ΔSPD_0410. The results showed that the Streptococcus pneumoniae load in the heart blood, lung tissue homogenate and spleen tissue homogenate of mice infected with D39ΔSPD_0410 defective bacteria was significantly higher than that of mice infected with wild D39 bacteria. This result shows that the loss of the spd0410 gene leads to increased virulence of Streptococcus pneumoniae.
[0213] In summary, the present application has found through research that by targeting the spd0410 gene (including itself and its homologous genes or alleles) and / or the protein encoded by the spd0410 gene, the activity of the corresponding gene and / or the expression level of its encoded protein can be adjusted, thereby changing the function and activity of the spd0410 gene and its encoded protein, so that the expression level of the capsular polysaccharide of Streptococcus pneumoniae changes, the surface capsule thickness changes, and ultimately the virulence of Streptococcus pneumoniae changes, thereby providing new targets for the prevention, treatment, prognosis assessment and treatment monitoring of diseases caused by Streptococcus pneumoniae infection.
[0214] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. An engineered Streptococcus pneumoniae, characterized in that: The genome of the engineered Streptococcus pneumoniae is completely or partially missing the spd0410 gene; Or, the activity of the spd0410 gene in the engineered Streptococcus pneumoniae is inhibited; and / or, the expression level of the protein encoded by the spd0410 gene in the engineered Streptococcus pneumoniae is reduced; The spd0410 gene includes itself and its homologous genes or alleles.
2. The method for preparing the engineered Streptococcus pneumoniae according to claim 1, characterized in that: The preparation method comprises: The spd0410 gene in Streptococcus pneumoniae is completely or partially deleted by gene knockout, gene knockdown, sequence point mutation or sequence point deletion; and / or, using a monoclonal antibody against spd0410, a polyclonal antibody against spd0410, a small molecule compound, a natural extract, CRISPR / Cas technology, SiRNA technology or a technology for changing the spd0410 promoter region to inhibit the activity of the spd0410 gene in Streptococcus pneumoniae and / or reduce the expression level of the protein encoded by the spd0410 gene in Streptococcus pneumoniae; The spd0410 gene includes itself and its homologous genes or alleles.
3. Use of engineered Streptococcus pneumoniae in the preparation of a vaccine for preventing diseases caused by Streptococcus pneumoniae infection, characterized in that: The genome of the engineered Streptococcus pneumoniae is completely or partially missing the spd0410 gene.
4. The use according to claim 3, characterized in that The disease comprises at least one of bacteremia, sepsis, pneumonia, meningitis, otitis media and endocarditis.
5. Use of a biological model in screening drugs for preventing or treating diseases caused by Streptococcus pneumoniae infection, characterized in that: The biological model includes engineered Streptococcus pneumoniae, the genome of which is entirely or partially missing the spd0410 gene, or the activity of the spd0410 gene is inhibited and / or the expression level of the protein encoded by the spd0410 gene is reduced, and the spd0410 gene includes itself and its homologous genes or alleles.
6. Use of the spd0410 gene and / or the protein encoded by the spd0410 gene as a target in the preparation of a method for diagnosing, evaluating the prognosis or evaluating the therapeutic effect of a disease caused by Streptococcus pneumoniae infection, characterized in that: The spd0410 gene or the protein is used as a biomarker for preparing or screening a diagnostic reagent for a disease caused by Streptococcus pneumoniae infection, and the reagent is used for diagnosis and / or prognosis and / or treatment monitoring of a disease caused by Streptococcus pneumoniae infection. The spd0410 gene includes itself and its homologous genes or alleles.
7. The use according to claim 6, characterized in that The reagent is used to determine the activity of the spd0410 gene and / or the expression level of the protein encoded by the spd0410 gene.
8. The use according to claim 6, characterized in that The activity of the spd0410 gene and / or the expression level of the protein encoded by the spd0410 gene is negatively correlated with the severity of the disease caused by Streptococcus pneumoniae infection.
9. The use according to claim 6, characterized in that The reagent is used for diagnosing or monitoring the existence and / or course and / or severity and / or prognosis of a disease caused by Streptococcus pneumoniae infection.
10. Use of the spd0410 gene and / or the protein encoded by the spd0410 gene as a target in the preparation of a drug for preventing or treating diseases caused by Streptococcus pneumoniae infection, characterized in that: The spd0410 gene includes itself and its homologous genes or alleles.
